Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) have been given an average recommendation of “Buy” by the fourteen brokerages that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $74.56.
Several research firms have recently commented on AERI. Zacks Investment Research raised Aerie Pharmaceuticals from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a report on Friday, March 22nd. BidaskClub downgraded Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, March 27th. Finally, Cantor Fitzgerald set a $85.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, February 26th.
In other Aerie Pharmaceuticals news, insider Casey C. Kopczynski sold 11,000 shares of the stock in a transaction on Friday, February 1st. The stock was sold at an average price of $46.17, for a total transaction of $507,870.00. Following the transaction, the insider now owns 97,243 shares in the company, valued at approximately $4,489,709.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.53% of the stock is owned by company insiders.
Hedge funds have recently bought and sold shares of the business. Truvestments Capital LLC acquired a new stake in shares of Aerie Pharmaceuticals during the first quarter valued at about $33,000. Handelsinvest Investeringsforvaltning boosted its stake in shares of Aerie Pharmaceuticals by 32.5% during the first quarter. Handelsinvest Investeringsforvaltning now owns 60,000 shares of the company’s stock valued at $2,850,000 after purchasing an additional 14,700 shares in the last quarter. Chartwell Investment Partners LLC boosted its stake in shares of Aerie Pharmaceuticals by 78.3% during the first quarter. Chartwell Investment Partners LLC now owns 42,313 shares of the company’s stock valued at $2,010,000 after purchasing an additional 18,578 shares in the last quarter. Tibra Equities Europe Ltd acquired a new stake in shares of Aerie Pharmaceuticals during the first quarter valued at about $922,000. Finally, American Century Companies Inc. boosted its stake in shares of Aerie Pharmaceuticals by 20.9% during the fourth quarter. American Century Companies Inc. now owns 89,429 shares of the company’s stock valued at $3,228,000 after purchasing an additional 15,472 shares in the last quarter.
NASDAQ:AERI traded up $0.81 during trading hours on Thursday, reaching $42.14. 17,671 shares of the stock were exchanged, compared to its average volume of 502,081. Aerie Pharmaceuticals has a twelve month low of $32.18 and a twelve month high of $74.75. The company has a market cap of $1.92 billion, a P/E ratio of -9.06 and a beta of 0.97.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Featured Article: How Do You Calculate Return on Equity (ROE)?